Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
AVITA Medical Lifts Guidance as Record Quarter Brings Cash Flow Breakeven into View
AVITA Medical lifts 2026 revenue guidance after record Q2 US$21.7m; eyes cash-flow breakeven in Q4 as RECELL-led growth broadens international reach.
Latest Stories — SECTOR DESK
Clarity Pharmaceuticals Adds Two Complete Responses to SECuRE Trial Data
Clarity Pharma reports two new complete responses at 8GBq in SECuRE trial, boosting radiographic disease control to seven; PSA declines strong.
BlinkLab Reports Positive ADHD Assessment Results from European Dx2 Diagnostic Platform Study
BlinkLab reports ADHD Dx2 results: 82% sensitivity, 83% specificity in European study, signaling new smartphone-based diagnostic tool.
Entropy Neurodynamics Gains Ethics Approval for Eight-Indication TRP-8803 Trial
Entropy Neurodynamics gains ethics approval for Phase 1b/2a eight-indication TRP-8803 basket trial; first dosing this quarter.
Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Paradigm Biopharmaceuticals Completes Phase 3 Enrolment Ahead of September Interim Analysis
Paradigm Biopharmaceuticals completes Phase 3 PARA_OA_012 enrolment for Zilosul in knee OA; interim analysis in Aug 2026; top-line results Q1 2027.
Adherium Reports Fourth Straight Quarter of Record RPM Revenue
Adherium logs fourth straight quarter of record RPM revenue, $479k to June, with 3,831 activated patients and a 68,000-patient pipeline as growth accelerates.
Imricor Launches US Operations with Cardiac Imaging System at Rady Children’s Hospital in San Diego
Imricor launches US ops with NorthStar MRI-guided cardiac mapping at Rady Children's after FDA paediatric clearance, enabling radiation-free procedures.
Adherium Outlines Commercial Progress and Value-Based Care Strategy
Adherium shifts to recurring respiratory care as RPM revenue surges 9.4x; 5,300 devices shipped, 2,600+ active patients, US$55/mo, targeting 10,000 by year-end.
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health boosts FY26 cash to net $2.3m, receipts $14.3m; pipeline over $12m as MRI liver fibrosis trial recruitment completes.
Clinuvel Looking to Access Greater Market Share with Corporate Restructure and US Relocation
Clinuvel relocates HQ to US, trims up to 20% staff, refocuses on US pipeline; Nasdaq listing aims to boost US investor access and partnerships.
Proteomics International Appoints Healius Exclusive Australian Distributor for Promarker Blood Tests
Proteomics inks exclusive Australian distributor deal with Healius for Promarker blood tests, enabling nationwide rollout by 2027; revenue not yet estimable.